This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (44)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Seven-Year Results

Robert B. Wainwright, MD, DTMH; Brian J. McMahon, MD; Lisa R. Bulkow, MS; Alan J. Parkinson, PhD; Annette P. Harpster, RN

Arch Intern Med. 1991;151(8):1634-1636.

Abstract
The long-term immunogenicity and protection provided by a plasma-derived hepatitis B vaccine (Heptavax B) was determined in a cohort of susceptible persons immunized in 1981. In this study 1581 susceptible persons were immunized with the recommended three-dose regimen of hepatitis B vaccine. After 7 years, 74% of vaccinees retained antibody to hepatitis B surface antigen (anti-HBs) levels of 10 mlU/mL or more. Anti-HBs levels at 7 years varied inversely with age and directly with the level of anti-HBs attained 1 year after the first dose. During the 7 years after the first dose of vaccine, five vaccine responders and three other persons developed antibody to hepatitis B core antigen and their level of anti-HBs increased. None developed detectable hepatitis B surface antigen or clinical hepatitis. This update of an ongoing study continues to suggest that the risk of hepatitis B virus infection to most persons with an initial anti-HBs response to hepatitis B virus vaccine of 10 mlU/mL or greater is low, regardless of the initial antibody level.

(Arch Intern Med. 1991;151:1634-1636)

Author Affiliations
From the Arctic Investigations Program, Center for Infectious Diseases, Centers for Disease Control, Public Health Service, US Department of Health and Human Services (Drs Wainwright and Parkinson and Mss Bulkow and Harpster) and Alaska Native Medical Center, Indian Health Service, Public Health Service, US Department of Health and Human Services (Dr McMahon), Anchorage, Alaska.

Footnotes
Accepted for publication January 17, 1991.

Reprint requests to the Arctic Investigations Program, Centers for Disease Control, 225 Eagle St, Anchorage, AK 99501 (Dr Wainwright).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antibody Levels and Protection after Hepatitis B Vaccination: Results of a 15-Year Follow-up
McMahon et al.
ANN INTERN MED 2005;142:333-341.
ABSTRACT | FULL TEXT  

Prevention of Hepatitis B with the Hepatitis B Vaccine
Poland and Jacobson
NEJM 2004;351:2832-2838.
FULL TEXT  

California Pediatricians' Knowledge of and Response to Recommendations for Universal Infant Hepatitis B Immunization
Wood et al.
Arch Pediatr Adolesc Med 1995;149:769-773.
ABSTRACT  

Assessment of Hepatitis B Virus Immunization Status Among North American Surgeons
Barie et al.
Arch Surg 1994;129:27-32.
ABSTRACT